Literature DB >> 8527553

Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.

H B Konradsen1.   

Abstract

It is not known how long vaccine-induced type-specific pneumococcal antibodies persist or whether age-related changes in their avidity occur; we therefore administered pneumococcal vaccine to 15 elderly persons aged 60-67 years to determine the level and avidity of the pneumococcal antibodies before vaccination and again 4 weeks and 5 years later. Antibody levels were significantly higher after vaccination than before vaccination in 67% of these subjects (P < .01). On the basis of guidelines established for revaccination, we found that 60% of these elderly persons required revaccination 5 years after primary immunization and that the antibody status of the remaining 40% would need to be determined some years later. No significant differences in IgG antibody avidity were detected in connection with the type of pneumococcus, the vaccination status of the vaccinee (i.e., whether sera were assayed before vaccination or 4 weeks or 5 years later), or the age of the vaccinee.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527553     DOI: 10.1093/clinids/21.3.616

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Conjugate vaccines.

Authors:  D Goldblatt
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  Prevalence of antimicrobial drug-resistant Streptococcus pneumoniae in Washington State.

Authors:  P A Frick; D J Black; J S Duchin; S Deliganis; W M McKee; T R Fritsche
Journal:  West J Med       Date:  1998-12

3.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential.

Authors:  Simon Athlin; Margit Kaltoft; Hans-Christian Slotved; Björn Herrmann; Hans Holmberg; Helle Bossen Konradsen; Kristoffer Strålin
Journal:  Clin Vaccine Immunol       Date:  2014-09-17

Review 5.  Pneumococcal disease in the elderly: what is preventing vaccine efficacy?

Authors:  J B Rubins; E N Janoff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  The effect of age on the response to the pneumococcal polysaccharide vaccine.

Authors:  Hyunju Lee; Moon H Nahm; Kyung-Hyo Kim
Journal:  BMC Infect Dis       Date:  2010-03-10       Impact factor: 3.090

7.  Correlation of pneumococcal antibody concentration and avidity with patient clinical and immunologic characteristics.

Authors:  Ari J Fried; Michelle L Altrich; Hongye Liu; John F Halsey; Francisco A Bonilla
Journal:  J Clin Immunol       Date:  2013-02-03       Impact factor: 8.317

8.  Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.

Authors:  Mehdi Mirsaeidi; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2014-07

9.  Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Authors:  Ken B Waites; Kay C Canupp; Yu-Ying Chen; Michael J DeVivo; Moon H Nahm
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 10.  Pneumococcal vaccination and revaccination of older adults.

Authors:  Andrew S Artz; William B Ershler; Dan L Longo
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.